Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences contingent consideration liability — MYR GmbH / Hepcludex ($M) ($M)
Form 10-Q / 10-K Note 3 Fair Value Measurements
Latest, Q2 2026
60
Period ended Jun 30, 2026
Change on a year earlier
-77.9%
271 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
21
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent consideration liability — MYR GmbH / Hepcludex ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 60 | -77.9% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 275 | +27.3% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 278 | +35.0% | Form 10-Q (filed 2026-08-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 274 | +23.4% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 271 | +30.3% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 216 | -2.7% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 206 | -9.6% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 222 | -19.3% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 208 | -27.8% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 222 | -19.9% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 228 | -17.1% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2023 | Sep 30, 2023 | 275 | +10.4% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 288 | -5.9% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 277 | -14.0% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 275 | -13.2% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 249 | -24.1% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 306 | -8.4% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 322 | -5.6% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 317 | – | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2021 | Sep 30, 2021 | 328 | – | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 334 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 341 | – | Form 10-K (filed 2022-02-23) ↗ |
| Q4 2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2022-02-23) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Contingent consideration liability — MYR GmbH / Hepcludex ($M) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/cc_liab_myr
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.